Clinical Study

Nrg-Hn005- Randomized Phase II And Phase III Studies Of Individualized Treatment For Nasopharyngeal Carcinoma Based On Biomarker Epstein Barr Virus (Ebv) Deoxyribonucleic Acid (Dna)

Posted Date: Nov 7, 2019

  • Investigator: Vinita Takiar
  • Specialties: Cancer, Head and Neck Cancer, Oncology
  • Type of Study: Drug

The goal of this study is to demonstrate non-inferiority in terms of progression-free survival (PFS) of concurrent reduced-dose radiation therapy (RT) with cisplatin or concurrent reduced-dose radiation therapy with nivolumab to the current standard of care

Criteria:

To Be Eligible: Diagnosed With Scc Of The Oropharynx, At Least 18 Yrs Of Age, Nonpregnant/Nonbreastfeeding, No Recurrent Disease, No Prior Metastatic Disease Within 3 Years, No Prior Treatment For Study Cancer, No Severe, Active Co-Morbitity

Keywords:

Head And Neck Cancer, Nasopharyngeal

For More Information:

Uc Cancer Institute
513-584-7698
cancer@uchealth.com


  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at ResearchStudies@UCHealth.com or (513) 245-3417.